GLSI CEO: Phase 2 Breast Cancer Vaccine Trial Prevented 80% of Recurrences

Greenwich Lifesciences (GLSI) is a company that focuses on preventing the recurrence of breast cancer after surgery. CEO Dr. Snehal Patel discusses how it can create a vaccine to help the immune system kill cancerous cells in tandem with other traditional treatments. “In our Phase 2 trial we prevented 80% or more” recurrences, he claims. They are currently running a Phase 3 trial, and he discusses recruiting patients around the world.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

Follow us on X – https://twitter.com/schwabnetwork

Follow us on Facebook – https://www.facebook.com/schwabnetwork

Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/

About Schwab Network - https://schwabnetwork.com/about